The role of anti-peripheral nerve myelin antibody (anti-PNM Ab) in the pathogenesis of acquired demyelination of peripheral nerve is unclear, in part, due to the poor correlation between antibody and disease activity. Previous studies show that only 27-50% of patients with acute demyelinating neuropathy or Guillain-Barre syndrome (GBS) had serum Abs to peripheral nerve or PNM as demonstrated by consumption of hemolytic activity of serum complement. In the present study by the use of a complement component 1 (Cl) fixation and transfer assay, quantitative determinations of anti-PNM Ab showed significantly high titers in the serum of patients with GBS, chronic and recurrent polyneuritis, and paraproteinemia associated with peripheral neuropathy. All 11 patients with acute-phase GBS had Ab titers 6-56 times higher than controls. In 6 GBS patients, serial Ab determinations showed that titers were highest on admission, fell rapidly the first week, and became undetectable or barely detectable by the third week. Declining Ab titers coincided with cessation of clinical progression. In 3 GBS patients, depletion of serum IgM lowered anti-PNM Ab titers significantly, whereas IgG depletion failed to produce a similar effect. This study shows that the C1 fixation and transfer assay is a sensitive method to detect anti-PNM Ab in the serum of patients with a variety of demyelinating neuropathies and provides good correlation between Ab level and the clinical course of GBS patients. It may provide important information about the pathogenesis of the demyelinating neuropathies.The primary demyelination of peripheral nerve seen in patients with Guillain-Barre Syndrome (GBS) or chronic and recurrent polyneuropathy is thought to represent immunologically mediated myelin destruction (1, 2). The role of the cellular and humoral immune system in initiation of myelin breakdown has not been defined. Antibodies (Abs) against peripheral nerve (3, 4), peripheral nerve myelin (PNM) (4-6), dorsal root ganglia (7), spinal cord tissue components (3), and neuroblastoma cells (8) have been identified in the serum of some GBS patients. However, it is not known whether these Abs actively participate in myelin destruction or whether they are an epiphenomenon reflecting a host response to PNM antigen(s) following myelin destruction. Recently a putative function for anti-PNM Abs in demyelination has been advanced by findings that some patients with monoclonal gammapathy develop demyelination and the monoclonal immunoglobulins are directed against PNM (6, 9). Serum from GBS patients as well as serum from patients with paraproteinemia associated with peripheral neuropathy can induce segmental demyelination following intraneural injection into rat and cat sciatic nerves (10-13).A reasonable hypothesis states that complement-activating, anti-PNM Abs may participate in peripheral nerve demyelination, particularly in light of the growing information on the membrane attack function of activated C5b-9 (14) and the C5b-9 requirement for Ab-mediated demy...